Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
Open Access
- 24 February 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (6) , 4467-4481
Abstract
Immunological data from cancer patients treated with Ad5/3 E2F Δ24 GMCSF suggests utility for tumor immunotherapy Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyKeywords
This publication has 56 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patientsProceedings of the National Academy of Sciences, 2012
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- The Role of Retinoic Acid in Tolerance and ImmunityImmunity, 2011
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nature Medicine, 2010
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSFMolecular Therapy, 2010
- A systematic review of humoral immune responses against tumor antigensCancer Immunology, Immunotherapy, 2009
- In situ adenovirus vaccination engages T effector cells against cancerVaccine, 2009
- Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian HamstersJournal of Virology, 2009
- The Hallmarks of CancerCell, 2000